On the forefront of healthcare change, turning innovative science into value for patients: Astellas at ASCO 2025 At this year ...

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...

Medical research charities LifeArc and Genetics Alliance UK have issued a call to the government to topple obstacles impeding ...

President Donald Trump took time out from the 4th July celebrations in the US to sign his One Big, Beautiful Bill Act (OBBBA) ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

The credit crunch has increased cost pressures on the pharmaceutical industry, Capgemini suggests that part of its response could be to open up a dialogue about the wider healthcare agenda. These ...

The most successful pharma sales teams will be those that define and service customers in new ways. Those who are the most responsive and relevant to today's customers and influencers will reap ...

Threshold Pharma is to move its pancreatic cancer drug into Phase 3, as investors get spooked by its failure to statistically improve overall survival. Threshold Pharma is to go ahead with Phase 3 ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie.

After turning down Takeda's Fruzaqla for metastatic colorectal cancer (mCRC) in draft guidance last year, NICE has changed its mind and recommended the drug for use by the NHS in England and Wales ...

We interview five healthcare professionals to get honest feedback on their views of pharma. First up is a male consultant who specialises in anaesthetics. To coincide with our medical ...